These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27336876)

  • 1. Clinical outcomes in cervical cancer patients treated by FDG-PET/CT-based 3-dimensional planning for the first brachytherapy session.
    Oh D; Huh SJ; Park W; Ju SG; Nam H; Lee JE
    Medicine (Baltimore); 2016 Jun; 95(25):e3895. PubMed ID: 27336876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
    Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
    Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
    Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proof of principle: Applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical cancer.
    Assenholt MS; Vestergaard A; Kallehauge JF; Mohamed S; Nielsen SK; Petersen JB; Fokdal L; Lindegaard JC; Tanderup K
    Brachytherapy; 2014; 13(4):361-8. PubMed ID: 24656732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computed Tomography-Guided Interstitial Brachytherapy for Locally Advanced Cervical Cancer: Introduction of the Technique and a Comparison of Dosimetry With Conventional Intracavitary Brachytherapy.
    Liu ZS; Guo J; Zhao YZ; Lin X; Zhang BY; Zhang C; Wang HY; Yu L; Ren XJ; Wang TJ
    Int J Gynecol Cancer; 2017 May; 27(4):768-775. PubMed ID: 28267131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical feasibility of interstitial brachytherapy using a "hybrid" applicator combining uterine tandem and interstitial metal needles based on CT for locally advanced cervical cancer.
    Liu ZS; Guo J; Lin X; Wang HY; Qiu L; Ren XJ; Li YF; Zhang BY; Wang TJ
    Brachytherapy; 2016; 15(5):562-9. PubMed ID: 27474180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes after positron emission tomography/computed tomography-based image-guided brachytherapy for cervical cancer.
    Kim N; Park W; Cho WK; Cho YS
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):743-750. PubMed ID: 35366364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical outcomes of ultrasound-guided CT-planned high-dose-rate interstitial brachytherapy for primary locally advanced cervical cancer.
    Mesko S; Swamy U; Park SJ; Borja L; Wang J; Demanes DJ; Kamrava M
    Brachytherapy; 2015; 14(5):626-32. PubMed ID: 26024784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional high dose rate intracavitary image-guided brachytherapy for the treatment of cervical cancer using a hybrid magnetic resonance imaging/computed tomography approach: feasibility and early results.
    Beriwal S; Kannan N; Kim H; Houser C; Mogus R; Sukumvanich P; Olawaiye A; Richard S; Kelley JL; Edwards RP; Krivak TC
    Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):685-90. PubMed ID: 21908180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses to the rectum and bladder.
    Hashim N; Jamalludin Z; Ung NM; Ho GF; Malik RA; Phua VC
    Asian Pac J Cancer Prev; 2014; 15(13):5259-64. PubMed ID: 25040985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis.
    Schmid MP; Kirisits C; Nesvacil N; Dimopoulos JC; Berger D; Pötter R
    Radiother Oncol; 2011 Sep; 100(3):468-72. PubMed ID: 21924510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
    Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
    Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study.
    Charra-Brunaud C; Harter V; Delannes M; Haie-Meder C; Quetin P; Kerr C; Castelain B; Thomas L; Peiffert D
    Radiother Oncol; 2012 Jun; 103(3):305-13. PubMed ID: 22633469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomography-based three-dimensional dosimetry of intracavitary brachytherapy for cervical cancer.
    Wadasaki K; Monzen Y; Kurose T; Okazaki H; Mito M
    Jpn J Radiol; 2010 Dec; 28(10):740-5. PubMed ID: 21191739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose positron emisson tomography/computed tomography guided conformal brachytherapy for cervical cancer.
    Nam H; Huh SJ; Ju SG; Park W; Lee JE; Choi JY; Kim BT; Kim CK; Park BK
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e29-34. PubMed ID: 22503526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-volume histogram parameters of high-dose-rate brachytherapy for Stage I-II cervical cancer (≤4cm) arising from a small-sized uterus treated with a point A dose-reduced plan.
    Nakagawa A; Ohno T; Noda SE; Kubo N; Kuwako K; Saitoh J; Nakano T
    J Radiat Res; 2014 Jul; 55(4):788-93. PubMed ID: 24566721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bladder distension on doses to organs at risk in Pulsed-Dose-Rate 3D image-guided adaptive brachytherapy for locally advanced cervical cancer.
    Nesseler JP; Charra-Brunaud C; Salleron J; Py JF; Huertas A; Meknaci E; Courrech F; Peiffert D; Renard-Oldrini S
    Brachytherapy; 2017; 16(5):976-980. PubMed ID: 28694116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interfraction variations in doses at OARs during three-dimensional high dose rate brachytherapy planning of cervix cancer.
    Dhaka S; Rajani A; Kumar HS; Sharma N; Jakhar SL; Harsh K
    J Cancer Res Ther; 2023; 19(5):1136-1141. PubMed ID: 37787275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer.
    Kim N; Park W; Cho WK; Bae DS; Kim BG; Lee JW; Kim TJ; Choi CH; Lee YY; Cho YS
    Cancer Res Treat; 2021 Jul; 53(3):803-812. PubMed ID: 33321566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.